Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
All content for The Swiss Connection is the property of SWI swissinfo.ch and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
Unveiling Ancient Life: Microorganisms in Melting Glaciers in Swiss Alps
The Swiss Connection
17 minutes
11 months ago
Unveiling Ancient Life: Microorganisms in Melting Glaciers in Swiss Alps
Send us a text This episode takes listeners to the Rhone glacier in the Alps, which is rapidly melting and releasing ancient microorganisms. These microorganisms, which have been trapped in the ice for thousands of years, are now being studied by scientists from the Swiss Federal Research Institute for Forest, Snow and Landscape (WSL). Journalists Céline Stegmüller and Luigi Jorio join the researchers on the glacier to observe their methods of collecting and analyzing these microorganisms. T...
The Swiss Connection
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
